---
document_datetime: 2025-12-02 06:00:53
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/byetta.html
document_name: byetta.html
version: success
processing_time: 0.1138198
conversion_datetime: 2025-12-28 02:25:59.682732
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Byetta

[RSS](/en/individual-human-medicine.xml/65512)

##### Authorised

This medicine is authorised for use in the European Union

exenatide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Byetta](#news-on)
- [More information on Byetta](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Byetta. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Byetta.

Expand section

Collapse section

## What is Byetta?

Byetta is a solution for injection that contains the active substance exenatide. It is available as prefilled injection pens that provide either 5 or 10 micrograms of exenatide in each dose.

## What is Byetta used for?

Byetta is used to treat type-2 diabetes. It is used together with other antidiabetes medicines in patients whose blood glucose (sugar) levels are not adequately controlled with the maximum tolerated doses of the other medicines. It can be used with metformin, sulphonylureas, thiazolidinediones, metformin and a sulphonylurea, or metformin and a thiazolidinedione.

Byetta can also be given to patients taking basal insulin (long-acting insulin such as insulin glargine) with or without metformin and / or pioglitazone (a thiazolidinedione) and whose blood glucose levels are not adequately controlled with these medicines.

The medicine can only be obtained with a prescription.

## How is Byetta used?

Byetta is given by injection under the skin of the thigh, the abdomen (tummy) or the upper arm, using the injection pen. The pen has a user manual.

Treatment with Byetta should start at a dose of 5 micrograms twice a day for at least a month. The dose can then be increased to 10 micrograms twice a day. A dose higher than 10 micrograms twice a day is not recommended. The first dose of the day is administered within the one hour before the morning meal, and the second dose within the one hour before the evening meal. Byetta should never be given after a meal. When adding Byetta to a sulphonylurea or basal insulin, the doctor may need to reduce the dose of the sulphonylurea or basal insulin because there is a risk of hypoglycaemia (low blood sugar levels). Adding Byetta to metformin or pioglitazone is not associated with this risk.

Patients being treated with Byetta should continue to follow their diet and exercise plans.

## How does Byetta work?

Type-2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. The active substance in Byetta, exenatide, is an 'incretin mimetic'. This means that it acts in the same way as incretins (hormones produced in the gut) by increasing the amount of insulin released by the pancreas in response to food. This helps with the control of blood glucose levels.

## How has Byetta been studied?

Byetta has been studied in eight main studies involving a total of around 3,000 patients whose blood glucose was not adequately controlled with other antidiabetes medicines.

In five of the studies, Byetta was compared with placebo (a dummy treatment), as an add-on to metformin (336 patients), sulphonylureas with or without metformin (1,110 patients) or thiazolidinediones with or without metformin (398 patients).

Two further studies compared adding Byetta or an insulin to metformin and sulphonylureas. In one study, Byetta was compared with insulin glargine in 456 patients and in the other study it was compared with biphasic insulin in 483 patients.

In another study involving 259 patients, Byetta was compared with placebo, as an add-on to insulin glargine. Patients were also taking either metformin or pioglitazone, or a combination of both.

In all of the studies, the main measure of effectiveness was the change in the levels of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled. At the start of the studies, the patients' HbA1c levels were around 8.4%.

## What benefit has Byetta shown during the studies?

Byetta was more effective than placebo in reducing the levels of HbA1c when used in combination with other antidiabetes medicines. When it was added to metformin and / or sulphonylureas, the 5-microgram dose of Byetta decreased HbA1c levels by an average of 0.59% after 30 weeks, and the 10-microgram dose decreased them by an average of 0.89%. When added to thiazolidinediones with or without metformin, the 10-microgram dose of Byetta reduced HbA1c levels by an average of 0.74% after 16 weeks and 0.84% after 26 weeks. Little or no effect was seen with placebo.

Byetta was as effective as injected insulin. The 10-microgram dose of Byetta decreased HbA1c by an average of 1.13% after 26 weeks, compared with an average of 1.10% with insulin glargine. In the final study, the 10-microgram dose of Byetta decreased HbA1c by an average of 1.01% after 52 weeks, compared with an average of 0.86% with biphasic insulin.

Byetta was more effective than placebo when it was given as add-on to insulin glargine (with or without other antidiabetes medications), as Byetta decreased HbA1c by an average of 1.7% compared with an average of 1.0% in patients taking placebo.

## What is the risk associated with Byetta?

In studies, the most common side effects with Byetta (seen in more than 1 patient in 10) were hypoglycaemia (when Byetta was used with sulphonylurea with or without metformin), nausea (feeling sick), vomiting and diarrhoea. For the full list of all side effects reported with Byetta, see the package leaflet.

Byetta must not be used in people who are hypersensitive (allergic) to exenatide or any of the other ingredients.

## Why has Byetta been approved?

The CHMP decided that Byetta's benefits are greater than its risks and recommended that it be given marketing authorisation.

## Other information about Byetta

The European Commission granted a marketing authorisation valid throughout the European Union for Byetta on 20 November 2006.

For more information about treatment with Byetta, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Byetta : EPAR - Summary for the public

English (EN) (62.36 KB - PDF)

**First published:** 18/02/2009

**Last updated:** 08/06/2012

[View](/en/documents/overview/byetta-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-662)

български (BG) (162.91 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/bg/documents/overview/byetta-epar-summary-public_bg.pdf)

español (ES) (122.82 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/es/documents/overview/byetta-epar-summary-public_es.pdf)

čeština (CS) (152.79 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/cs/documents/overview/byetta-epar-summary-public_cs.pdf)

dansk (DA) (123.45 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/da/documents/overview/byetta-epar-summary-public_da.pdf)

Deutsch (DE) (124.26 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/de/documents/overview/byetta-epar-summary-public_de.pdf)

eesti keel (ET) (62.86 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/et/documents/overview/byetta-epar-summary-public_et.pdf)

ελληνικά (EL) (166.14 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/el/documents/overview/byetta-epar-summary-public_el.pdf)

français (FR) (138.92 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/fr/documents/overview/byetta-epar-summary-public_fr.pdf)

italiano (IT) (125.48 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/it/documents/overview/byetta-epar-summary-public_it.pdf)

latviešu valoda (LV) (92.84 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/lv/documents/overview/byetta-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (88.84 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/lt/documents/overview/byetta-epar-summary-public_lt.pdf)

magyar (HU) (146.33 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/hu/documents/overview/byetta-epar-summary-public_hu.pdf)

Malti (MT) (150.65 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/mt/documents/overview/byetta-epar-summary-public_mt.pdf)

Nederlands (NL) (123.26 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/nl/documents/overview/byetta-epar-summary-public_nl.pdf)

polski (PL) (151.92 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/pl/documents/overview/byetta-epar-summary-public_pl.pdf)

português (PT) (123.64 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/pt/documents/overview/byetta-epar-summary-public_pt.pdf)

română (RO) (149.23 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/ro/documents/overview/byetta-epar-summary-public_ro.pdf)

slovenčina (SK) (149.19 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/sk/documents/overview/byetta-epar-summary-public_sk.pdf)

slovenščina (SL) (146.53 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/sl/documents/overview/byetta-epar-summary-public_sl.pdf)

Suomi (FI) (125.67 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/fi/documents/overview/byetta-epar-summary-public_fi.pdf)

svenska (SV) (122.14 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

08/06/2012

[View](/sv/documents/overview/byetta-epar-summary-public_sv.pdf)

Byetta : EPAR - Risk-management-plan summary

English (EN) (365.15 KB - PDF)

**First published:** 24/05/2023

[View](/en/documents/rmp-summary/byetta-epar-risk-management-plan-summary_en.pdf)

## Product information

Byetta : EPAR - Product Information

English (EN) (1.36 MB - PDF)

**First published:** 25/06/2009

**Last updated:** 06/11/2024

[View](/en/documents/product-information/byetta-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-632)

български (BG) (1.46 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/bg/documents/product-information/byetta-epar-product-information_bg.pdf)

español (ES) (4.16 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/es/documents/product-information/byetta-epar-product-information_es.pdf)

čeština (CS) (1.12 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/cs/documents/product-information/byetta-epar-product-information_cs.pdf)

dansk (DA) (1.06 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/da/documents/product-information/byetta-epar-product-information_da.pdf)

Deutsch (DE) (1.4 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/de/documents/product-information/byetta-epar-product-information_de.pdf)

eesti keel (ET) (1.23 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/et/documents/product-information/byetta-epar-product-information_et.pdf)

ελληνικά (EL) (1.16 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/el/documents/product-information/byetta-epar-product-information_el.pdf)

français (FR) (1.13 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/fr/documents/product-information/byetta-epar-product-information_fr.pdf)

hrvatski (HR) (1.1 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/hr/documents/product-information/byetta-epar-product-information_hr.pdf)

íslenska (IS) (1.09 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/is/documents/product-information/byetta-epar-product-information_is.pdf)

italiano (IT) (1.09 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/it/documents/product-information/byetta-epar-product-information_it.pdf)

latviešu valoda (LV) (4.17 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/lv/documents/product-information/byetta-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.08 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/lt/documents/product-information/byetta-epar-product-information_lt.pdf)

magyar (HU) (1.13 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/hu/documents/product-information/byetta-epar-product-information_hu.pdf)

Malti (MT) (1.52 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/mt/documents/product-information/byetta-epar-product-information_mt.pdf)

Nederlands (NL) (960.36 KB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/nl/documents/product-information/byetta-epar-product-information_nl.pdf)

norsk (NO) (886.07 KB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/no/documents/product-information/byetta-epar-product-information_no.pdf)

polski (PL) (1.12 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/pl/documents/product-information/byetta-epar-product-information_pl.pdf)

português (PT) (1.33 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/pt/documents/product-information/byetta-epar-product-information_pt.pdf)

română (RO) (1.16 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/ro/documents/product-information/byetta-epar-product-information_ro.pdf)

slovenčina (SK) (1.45 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/sk/documents/product-information/byetta-epar-product-information_sk.pdf)

slovenščina (SL) (1.43 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/sl/documents/product-information/byetta-epar-product-information_sl.pdf)

Suomi (FI) (1.32 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/fi/documents/product-information/byetta-epar-product-information_fi.pdf)

svenska (SV) (1.03 MB - PDF)

**First published:**

25/06/2009

**Last updated:**

06/11/2024

[View](/sv/documents/product-information/byetta-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IA/0082 05/11/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Byetta : EPAR - All Authorised presentations

English (EN) (15.13 KB - PDF)

**First published:** 12/12/2006

**Last updated:** 12/12/2006

[View](/en/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-508)

български (BG) (113.38 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/bg/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_bg.pdf)

español (ES) (15.94 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/es/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_es.pdf)

čeština (CS) (100.27 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/cs/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (15.8 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/da/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (15.86 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/de/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (15.96 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/et/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (93.12 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/el/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_el.pdf)

français (FR) (15.65 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/fr/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (15.27 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/it/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (100.57 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/lv/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (99.93 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/lt/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (98.36 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/hu/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (50.28 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/mt/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (15.23 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/nl/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_nl.pdf)

polski (PL) (109.98 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/pl/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_pl.pdf)

português (PT) (15.87 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/pt/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_pt.pdf)

română (RO) (112.84 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/ro/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (99.63 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/sk/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (15.69 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/sl/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (15.72 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/fi/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (15.9 KB - PDF)

**First published:**

12/12/2006

**Last updated:**

12/12/2006

[View](/sv/documents/all-authorised-presentations/byetta-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Byetta Active substance exenatide International non-proprietary name (INN) or common name exenatide Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BJ01

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Byetta is indicated for treatment of type-2 diabetes mellitus in combination with:

- metformin;
- sulphonylureas;
- thiazolidinediones;
- metformin and a sulphonylurea;
- metformin and a thiazolidinedione;

in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies. Byetta is also indicated as adjunctive therapy to basal insulin with or without metformin and / or pioglitazone in adults who have not achieved adequate glycaemic control with these agents.

## Authorisation details

EMA product number EMEA/H/C/000698 Marketing authorisation holder

AstraZeneca AB

151 85 Sodertalje

Marketing authorisation issued 20/11/2006 Revision 30

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Byetta : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (289.55 KB - PDF)

**First published:** 25/06/2009

**Last updated:** 06/11/2024

[View](/en/documents/procedural-steps-after/byetta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Byetta-PSUSA-00009147-202003 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/120245/2021

English (EN) (160.62 KB - PDF)

**First published:** 01/03/2021

[View](/en/documents/scientific-conclusion/byetta-psusa-00009147-202003-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Byetta-PSUSA-00009147-201503 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/772251/2015

English (EN) (67.79 KB - PDF)

**First published:** 28/01/2016

**Last updated:** 28/01/2016

[View](/en/documents/scientific-conclusion/byetta-psusa-00009147-201503-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Byetta-H-C-698-PSUV-0045 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/136381/2015

English (EN) (64.12 KB - PDF)

**First published:** 09/03/2015

**Last updated:** 09/03/2015

[View](/en/documents/scientific-conclusion/byetta-h-c-698-psuv-0045-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Byetta-H-C-698-II-0029 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/363251/2012

English (EN) (1011.7 KB - PDF)

**First published:** 07/06/2012

**Last updated:** 07/06/2012

[View](/en/documents/variation-report/byetta-h-c-698-ii-0029-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Byetta

Adopted

Reference Number: EMA/CHMP/113061/2012

English (EN) (110.75 KB - PDF)

**First published:** 17/02/2012

**Last updated:** 17/02/2012

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-byetta_en.pdf)

Byetta-H-C-698-II-0021 : EPAR - Assessment Report - Variation

Adopted

Reference Number: ema/372238/2010

English (EN) (480.1 KB - PDF)

**First published:** 08/10/2010

**Last updated:** 08/10/2010

[View](/en/documents/variation-report/byetta-h-c-698-ii-0021-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Byetta

Adopted

English (EN) (75.14 KB - PDF)

**First published:** 25/06/2010

**Last updated:** 25/06/2010

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-byetta_en.pdf-0)

## Initial marketing authorisation documents

Byetta : EPAR - Procedural steps taken before authorisation

English (EN) (27.8 KB - PDF)

**First published:** 15/12/2006

**Last updated:** 15/12/2006

[View](/en/documents/procedural-steps/byetta-epar-procedural-steps-taken-authorisation_en.pdf)

Byetta : EPAR - Scientific Discussion

English (EN) (218.06 KB - PDF)

**First published:** 15/12/2006

**Last updated:** 15/12/2006

[View](/en/documents/scientific-discussion/byetta-epar-scientific-discussion_en.pdf)

#### News on Byetta

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024) 12/04/2024

[EMA statement on ongoing review of GLP-1 receptor agonists](/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists) 11/07/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2013) 26/07/2013

[Investigation into GLP-1-based diabetes therapies concluded](/en/news/investigation-glp-1-based-diabetes-therapies-concluded) 26/07/2013

[European Medicines Agency investigates findings on pancreatic risks with GLP-1-based therapies for type-2 diabetes](/en/news/european-medicines-agency-investigates-findings-pancreatic-risks-glp-1-based-therapies-type-2-diabetes) 26/03/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 February 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-february-2012) 17/02/2012

#### More information on Byetta

- [EMEA-000689-PIP01-09-M11 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000689-pip01-09-m11)
- [Incretin-based therapies and Pancreatic Cancer risk in Medicare enrollees - new user protocol - post-authorisation study](https://catalogues.ema.europa.eu/study/8912)
- [Incidence of Pancreatic Malignancy and Thyroid Neoplasm in Type 2 Diabetes Mellitus Patients who Initiate Exenatide Compared to Other Antihyperglycemic Drugs - Phase 2 (Extended Accrual and Follow-Up) - post-authorisation study](https://catalogues.ema.europa.eu/study/24671)
- [Exenatide (Byetta subcutaneous injection) Specific Clinical Experience Investigation for long-term use (PMS Byetta Long Term Use SCEI) - post-authorisation study](https://catalogues.ema.europa.eu/study/37369)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 06/11/2024

## Share this page

[Back to top](#main-content)